BRIDGEWATER, NJ--(MARKET WIRE)--Aug 21, 2007 -- Alpharma Inc. (NYSE:ALO - News) today announced it has reached agreement with Institut Biochimique SA ("IBSA"), a privately-owned, global pharmaceutical company headquartered in Lugano, Switzerland, to obtain exclusive license and distribution rights to market the Flector® Patch, the first prescription topical NSAID (non-steroidal anti-inflammatory drug) patch approved by the FDA in the United States. The Flector® Patch, which delivers the anti-inflammatory and analgesic effects of patent-protected diclofenac epolamine, is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. IBSA currently markets this product in Europe, and Alpharma is targeting a U.S. launch for early 2008.
